Peg-IFN-alpha treatment in HBeAg-negative chronic hepatitis B yields virological and serological responses.
New Blood Test Predicts Hep B Drug Success
This prospective cohort study evaluated HBeAg-negative chronic hepatitis B patients treated with pegylated interferon alpha over 48 weeks. V…
A new blood test checks specific genes to predict if hepatitis B patients will respond to treatment before wasting months on ineffective med…
Meta-analysis of 50 studies shows indeterminate chronic hepatitis B affects 39% of patients with elevated HCC risk.
Four in Ten Hepatitis B Patients Live in a Medical Gray Zone
This systematic review and meta-analysis pooled data from 50 studies involving patients with chronic hepatitis B classified as indeterminate…
A huge share of hepatitis B patients sit in limbo between guidelines, and a new analysis shows that limbo is not as safe as it sounds.
Pegylated interferon-alpha toxicity mechanisms and management in chronic hepatitis B patients
New Way to Handle Painful Side Effects of Hepatitis B Drug
This systematic review examined mechanisms and management of pegylated interferon-alpha toxicity in patients with chronic hepatitis B. The a…
A powerful hepatitis B drug can cause severe flu-like symptoms and other painful reactions, but new strategies aim to manage these side effe…
Hepatic steatosis compromises APRI and FIB-4 accuracy for staging fibrosis in chronic hepatitis B patients.
Does fatty liver ruin the accuracy of common blood tests for scarring in hepatitis B?
This retrospective cohort study evaluated treatment-naïve Han Chinese patients with chronic hepatitis B to assess how concurrent hepatic ste…
Fatty liver makes common blood tests for hepatitis B scarring nearly useless, dropping accuracy from 90% to under 50% and causing dangerous …
HBV RNA positivity at nucleoside analogue discontinuation linked to higher relapse risk in chronic hepatitis B
What happens when hepatitis B patients stop their medication? A key marker may predict relapse.
A meta-analysis of 21 cohort studies including 2,043 chronic hepatitis B patients found HBV RNA-positive individuals had 1.9-fold higher vir…
Stopping hepatitis B medication carries higher relapse risk if a specific viral marker called HBV RNA is still detectable in the blood.